 |
A 2015 paper details 2 patients with severe flushing and redness being treated with injections of Botox.
The first patient had suffered 2 years of flushing and erythema triggered by heat, sun exposure, stress, spicy food and cosmetics. The second patient had suffered from 3 years of redness and flushing. Both had tried a series of treatments unsuccessfully.
The paper tells us that both patients reported satisfactory results and returned for a repeat treatment after 4 months. As only 2 rosacea sufferers were studied, the authors caution that the use of botulinum toxin injections to treat rosacea requires more study.
For some more background on treating rosacea related flushing with Botox see Botox User Reviews.
Botulinum Toxin for the Treatment of Refractory Erythema and Flushing of Rosacea
Dermatology 2015;230:299-301
Background: Persistent erythema and severe rosacea flushing can cause significant physical discomfort and emotional stress to patients. Currently, no satisfactory treatments are available.
Methods: We report two cases of refractory flushing and erythema of rosacea that were successfully treated with intradermal botulinum toxin injections.
Results: Good cosmetic results were achieved for both patients. The side effects during and after treatment were mild pain and localized bruising; these symptoms resolved within several days without further treatment.
Conclusion:Intradermal botulinum toxin injection may be an effective treatment for refractory erythema and rosacea flushing that deserves further study in a larger patient population.
Treatment Details
The paper gives good details about how the treatment was administered.
The patient received two treatments of intradermal botulinum toxin injections at 1-week intervals.
Each vial of onabotulinum toxinA, which contained 50 U of Clostridium botulinum toxin type A with human serum albumin and sodium chloride (botulinum toxin A, purified neurotoxin complex; Allergan, Campbell, Calif., USA), was reconstituted with 2.5 ml of sterile saline to achieve a concentration of 2 U/0.1 ml.
A lidocaine-based topical anesthetic cream (EMLA; AstraZeneca, London, UK) was applied 1 h before treatment. A 30-gauge insulin syringe was used for the injection. The injection points were staggered 1 cm apart to cover the entirety of the erythematous lesions of the face. The toxin was injected vertically at a 90° angle. The total dose of botulinum toxin in two treatments was 50 U.
